1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM)
Publication
, Conference
McMurray, JJ; Lang, CC; Swedberg, K; Östergren, J; Granger, CB; Michelson, E; Young, JB; Olofsson, B; Dunlap, M; Yusuf, S; Pfeffer, MA
Published in: Journal of the American College of Cardiology
March 2004
Duke Scholars
Published In
Journal of the American College of Cardiology
DOI
ISSN
0735-1097
Publication Date
March 2004
Volume
43
Issue
5
Start / End Page
A197 / A197
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
McMurray, J. J., Lang, C. C., Swedberg, K., Östergren, J., Granger, C. B., Michelson, E., … Pfeffer, M. A. (2004). 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). In Journal of the American College of Cardiology (Vol. 43, pp. A197–A197). Elsevier BV. https://doi.org/10.1016/s0735-1097(04)90836-4
McMurray, John J., Chim C. Lang, Karl Swedberg, Jan Östergren, Christopher B. Granger, Eric Michelson, James B. Young, et al. “1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM).” In Journal of the American College of Cardiology, 43:A197–A197. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)90836-4.
McMurray JJ, Lang CC, Swedberg K, Östergren J, Granger CB, Michelson E, et al. 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). In: Journal of the American College of Cardiology. Elsevier BV; 2004. p. A197–A197.
McMurray, John J., et al. “1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM).” Journal of the American College of Cardiology, vol. 43, no. 5, Elsevier BV, 2004, pp. A197–A197. Crossref, doi:10.1016/s0735-1097(04)90836-4.
McMurray JJ, Lang CC, Swedberg K, Östergren J, Granger CB, Michelson E, Young JB, Olofsson B, Dunlap M, Yusuf S, Pfeffer MA. 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM). Journal of the American College of Cardiology. Elsevier BV; 2004. p. A197–A197.
Published In
Journal of the American College of Cardiology
DOI
ISSN
0735-1097
Publication Date
March 2004
Volume
43
Issue
5
Start / End Page
A197 / A197
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology